PALISMALL

Palisade Bio, Inc.

HealthcareBiotechnology
$1.89
$0.00(+5.00%)
52W$0.53
$2.85
Updated Jun 28, 02:00 AM
RSI47
RS Rating53/99
Beta1.49
Volatility125%
F-Score4/9
Mkt Cap$396M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Palisade Bio, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 53), indicating performance broadly in line with the market. Earnings growth of 90% provides fundamental context to the price action. Investors should exercise caution due to high volatility (125% annualized), which requires wider risk management.

Relative Strength
53
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.49
vs S&P 500
ABOVE MKT
52W Position
58%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$1.96
50 SMA > 100 SMA$1.90
100 SMA > 150 SMA$1.92
150 SMA > 200 SMA$1.81

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$1.84+2.86%ABOVE
50 SMA$1.96-3.61%BELOW
100 SMA$1.90-0.35%BELOW
150 SMA$1.92-1.37%BELOW
200 SMA$1.81+4.49%ABOVE

Price Performance

1D+5.0%
1W+2.7%
1M-5.0%
3M-3.6%
6M-12.1%
YTD-24.4%
1Y+164.8%
3Y-57.7%
52-Week Trading Range58% from low
$1.89
52W Low$0.53
52W High$2.85

Technical Indicators

RSI (14)NEUTRAL
46.6
305070
Setup ScoreCOOL
4/10
Base depth: 64.3%

Risk Profile

Beta
1.49
52W Vol
125%
ATR
$0.12
Max DD (1Y)
-57%

Volume Analysis

Today
50D Avg
3.09M
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q2'25+83%
$-0.58
Q3'25+84%
$-0.38
Q4'25+86%
$-0.06
Q1'26+90%
$-0.05
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:+47.74%
5 Years:
3 Years:
TTM:+83.64%

Stock Price CAGR

10 Years:-69.96%
5 Years:-77.48%
3 Years:-57.66%
1 Year:+164.78%

Return on Equity

10Y Avg:-2341.2%
5Y Avg:-4087.4%
3Y Avg:-93.8%
Last Year:-36.8%

Key Metrics

Market Cap$396M
Gross Margin
Net Margin
Piotroski F-Score4/9

Frequently Asked Questions

Is PALI in an uptrend right now?

PALI has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is PALI overbought or oversold?

PALI's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.

Is PALI outperforming the market?

PALI has a Relative Strength (RS) Rating of 53 out of 99. PALI is performing about average compared to the market.

Where is PALI in its 52-week range?

PALI is trading at $1.89, which is 66% of its 52-week high ($2.85) and 58% above its 52-week low ($0.53).

How volatile is PALI?

PALI has a Beta of 1.49 and 52-week volatility of 125%. It's more volatile than the S&P 500 - expect bigger swings.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.